Processing

Please wait...

Settings

Settings

Goto Application

1. WO2011009637 - MARKERS FOR ENDOMETRIAL CANCER

Publication Number WO/2011/009637
Publication Date 27.01.2011
International Application No. PCT/EP2010/004550
International Filing Date 23.07.2010
IPC
C12Q 1/68 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
CPC
C07K 16/3069
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
3069Reproductive system, e.g. ovaria, uterus, testes, prostate
C07K 2317/34
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
C12Q 1/6837
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6813Hybridisation assays
6834Enzymatic or biochemical coupling of nucleic acids to a solid phase
6837using probe arrays or probe chips
C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
C12Q 2600/112
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
112Disease subtyping, staging or classification
C12Q 2600/156
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
156Polymorphic or mutational markers
Applicants
  • GEADIC BIOTEC, AIE. [ES]/[ES] (AllExceptUS)
  • ABAL POSADA, Miguel [ES]/[ES] (UsOnly)
  • DOLL, Andreas [ES]/[ES] (UsOnly)
  • GIL MORENO, Antonio [ES]/[ES] (UsOnly)
  • MAES, Tamara [BE]/[ES] (UsOnly)
  • PEREZ, Cristina [ES]/[ES] (UsOnly)
  • REVENTÓS PUIGJANER, Jaume [ES]/[ES] (UsOnly)
  • ROSSELL, Elisabet [ES]/[ES] (UsOnly)
Inventors
  • ABAL POSADA, Miguel
  • DOLL, Andreas
  • GIL MORENO, Antonio
  • MAES, Tamara
  • PEREZ, Cristina
  • REVENTÓS PUIGJANER, Jaume
  • ROSSELL, Elisabet
Agents
  • VOSSIUS & PARTNER
Priority Data
09166398.924.07.2009EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) MARKERS FOR ENDOMETRIAL CANCER
(FR) MARQUEURS DE CANCER ENDOMÉTRIAL
Abstract
(EN)
The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1 R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, S0CS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and/or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values. Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected individuals.
(FR)
L'invention porte sur la découverte surprenante selon laquelle des biomarqueurs correspondant à ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1 R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, S0CS2 et DCN sont exprimés différentiellement dans des échantillons témoins par comparaison à des échantillons provenant de patients atteints d'un cancer endométrial et sont par conséquent utiles pour détecter un cancer endométrial. En particulier, ces biomarqueurs ont d'excellentes sensibilité, spécificité et/ou la capacité de séparer des individus atteints d'individus non atteints. En outre, les inventeurs ont découvert que l'expression différentielle de ces biomarqueurs dans un tissu tumoral de cancer endométrial primaire est corrélée à leur niveau d'expression dans des échantillons de fluide utérin par comparaison des valeurs témoins. Ainsi, ces biomarqueurs sont robustes en ce qu'il a été observé qu'ils sont exprimés différentiellement dans plusieurs types différents d'échantillons provenant d'individus atteints.
Latest bibliographic data on file with the International Bureau